1. Pink Sheet
  2. >>Geography
  3. >>Asia
  4. >>South Korea

No Korea-Originated New Drugs Approved Domestically In 2023

But Carvykti Becomes Second CAR-T

 
• By Jung Won Shin

Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.

various drugs
Korea’s Homegrown Novel Drug Approvals Continue To Drop • Source: Shutterstock

Drug approvals in South Korea fell in calendar 2023 amid the shift of COVID-19 to endemic from pandemic status, as domestic pharma firms began to shift their focus back to normalized R&D activities after the rush to develop therapeutics and vaccines against SARS-CoV-2.

Among the notable marketing nods was that for Janssen Biotech Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Asia

Japan Looks To Build Domestic Capacity In New Modalities

 
• By Lisa Takagi

Japan's trade ministry is providing new support to build domestic capacity for new modalities including cell and gene therapies, as part of wider efforts to support the national bioventure ecosystem.

Pipeline To Product – What Is Driving Cell And Gene Therapy Progress In India?

 
• By Vibha Ravi

US-based Colossal Labs has claimed to bring back the dire wolf from extinction. While the science is not as dramatic in India yet, cell and gene therapies are making progress as treatments for cancer and other diseases. Pink Sheet takes a look at what is driving CGT success and growth.

Japan Identifies Drugs ‘In Urgent Need’ Of Development

 
• By Lisa Takagi

Artesunate for malaria, TB drug pretomanid and omadacycline for pneumonia and skin infections are among the drugs identified by Japanese regulatory authorities in urgent need of domestic development.